The selective estrogen receptor modulators in breast cancer prevention

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 5, 2016, Pages 895-903

  Li, Fangxuan ^a   Dou, Jinli ^a   Wei, Lijuan ^a   Li, Shixia ^a   Liu, Juntian ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; BRCA1 PROTEIN; BRCA2 PROTEIN; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; ESTROGEN RECEPTOR;

ADVERSE OUTCOME; ATRIAL FIBRILLATION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ENDOMETRIUM CANCER; GENE MUTATION; HEADACHE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOEMBOLISM; UROGENITAL TRACT DISEASE; BREAST NEOPLASMS; DOSE RESPONSE; ECONOMICS; FEMALE; METABOLISM; RISK FACTOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; RALOXIFENE HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84954570416     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2959-0     Document Type: Review

References (56)

1. Mandelblatt JS, Tosteson AN, van Ravesteyn NT (2013) Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control. JAMA Intern Med 173 (3): 227-228
2. DeSantis C et al (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64 (1): 52-62
3. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354 (3): 270-282
4. Garcia-Closas M, Gunsoy NB, Chatterjee N (2014) Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst 106 (11): 1-6
5. Reimers L, Crew KD (2012) Tamoxifen versus raloxifene versus exemestane for chemoprevention. Curr Breast Cancer Rep 4 (3): 207-215
6. Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371-1388
7. Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (22): 1652-1662
8. Veronesi U et al (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95 (2): 160-165
9. Veronesi U et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (9): 727-737
10. Powles T et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98-101
11. Powles TJ et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (4): 283-290
12. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (4): 272-282
13. Cuzick J et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (9336): 817-824
14. Cuzick J et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16 (1): 67-75
15. Malone KE et al (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279 (12): 922-929
16. King MC et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABPP1) Breast Cancer Prevention Trial. JAMA 286 (18): 2251-2256
17. Kote-Jarai Z et al (2007) BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Lett 247 (2): 259-265
18. Xu L et al (2015) Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer 22 (4): 327-334
19. Phillips KA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31 (25): 3091-3099
20. Detterbeck F, Tanoue L, Reid A (2013) National comprehensive cancer network. J Natl Compr Canc Netw 11 (4): 365-366
21. Phillips KA, Lindeman GJ (2014) Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: Is there a role for tamoxifen? Future Oncol 10 (4): 499-502
22. Advani P, Moreno-Aspitia A (2014) Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) 6: 59-71
23. Cuzick J et al (2003) Overview of the main outcomes in breastcancer prevention trials. Lancet 361 (9354): 296-300
24. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (9114): 1451-1467
25. Maltoni C et al (1996) Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In: Maltoni C, Soffritti M, Davis W (eds) The scientific bases of cancer chemoprevention. Elsevier Science BV, Amsterdam, pp 197-207
26. Decensi A et al (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90 (19): 1461-1467
27. Decensi A et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95 (11): 779-790
28. de Lima GR et al (2003) Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39 (7): 891-898
29. Decensi A et al (2007) Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol 25 (27): 4201-4209
30. Decensi A, Galli A, Veronesi U (2003) HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results Cancer Res 163: 104-111 discussion 264-6
31. DeCensi A et al (2013) A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol 24 (11): 2753-2760
32. Smith TJ, Hillner BE (2000) Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol 18 (2): 284-286
33. Hershman D et al (2002) Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol 20 (1): 9-16
34. Hartmann LC et al (2015) A typical hyperplasia of the breast— risk assessment and management options. N Engl J Med 372 (1): 78-89
35. Cykert S, Phifer N, Hansen C (2004) Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 104 (3): 433-442
36. Melnikow J et al (2006) Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 107 (5): 950-958
37. Eckermann SD et al (2003) The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health 27 (1): 34-40
38. Kondo M, Hoshi SL, Toi M (2009) Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer 100 (2): 281-290
39. Bevers TB (2007) The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5 (8): 719-724
40. Cauley JA et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2): 125-134
41. Martino S et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (23): 1751-1761
42. Barrett-Connor E et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2): 125-137
43. Vogel VG et al (2006) Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727-2741
44. Vogel VG et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 3 (6): 696-706
45. Armstrong K et al (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98 (6): 996-1003
46. Cummings SR et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362 (8): 686-696
47. LaCroix AZ et al (2010) Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102 (22): 1706-1715
48. Cummings SR et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26 (2): 397-404
49. Powles TJ et al (2012) Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat 134 (1): 299-306
50. Ellis AJ et al (2015) Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf 14 (6): 921-934
51. Lewis-Wambi JS et al (2011) The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 80 (4): 610-620
52. Silverman SL et al (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23 (1): 351-363
53. Cuzick J et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (9880): 1827-1834
54. Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27 (19): 3235-3258
55. Bevers TB et al (2010) Breast cancer risk reduction. J Natl Compr Canc Netw 8 (10): 1112-1146
56. Waters EA et al (2012) Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 134 (2): 875-880